AVPR2 and nephrogenic diabetes insipidus: Such favorable PK have also been seen for the GnRHR-targeting PC discussed above (11) as well as in the case of PCs targeting the vasopressin V2 receptor for the treatment of nephrogenic diabetes insipidus in humans (12).